A Phase 2 interventional study of Plinabulin and Pegfilgrastim in Chemotherapy-induced Neutropenia, sponsored by BeyondSpring Pharmaceuticals Inc.. Completed at 19 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by BeyondSpring Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Neutropenia with a site in Ukraine — 1 open to participants now, 2 under way, 2 of them phase 3. Neutropenia · Ukraine.
Among the 12 studies in Neutropenia with a site in Ukraine, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 11th registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →1 of the 12 studies in Neutropenia with a site in Ukraine is open now. Recruiting first, the newest first:
X4 Pharmaceuticals · Sites in Ukraine, United States, Argentina and 22 more countries
Ages 12+
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 185 across the 12 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 7 most frequent:
BeyondSpring Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
BeyondSpring Pharmaceuticals Inc. has 4 studies filed under Neutropenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Neutropenia with a site in Ukraine that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Neutropenia with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count was to be assessed at baseline (prior to Cycle 1 docetaxel dose) and during Cycle 1 on Days 1, 2, 6, 7, 8, 9, 10, and 15 (pre-dose on dosing days; times equivalent to pre dose on other days).
55 patients with advanced and metastatic NSCLC have been randomized with the arm designation and planned intervention as follows: Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) Arm 2: Docetaxel (75 mg/m2) + plinabulin (20 mg/m\^2) Arm 3: Docetaxel (75 mg/m2) + plinabulin (10 mg/m\^2) Arm 4: Docetaxel (75 mg/m2) + plinabulin (5 mg/m\^2)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with:
Advanced or NSCLC failing platinum based therapy
Patients with ≥1 of the following risk factors, at the initiation of docetaxel chemotherapy, that would require neutropenia prophylaxis per National Comprehensive Cancer Network (NCCN) guidelines (version 2, 2016) Myeloid Growth Factors:
The following laboratory results assessed within 14 days prior to study drug administration:
≥ 9 g/dL independent of transfusion or growth factor support ≥ 1.5 x 109/L independent of growth factor support Serum total ≤ 1.5 times the upper limit normal (), unless the patient has a diagnosis of Gilbert's disease in which case direct bilirubin ≤ 1.5 times ULN of the direct bilirubin.
(AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤1.5 x ULN if alkaline phosphatase [AP] is > 2.5 x ULN) Serum creatinine ≤ 1.5 x ULN
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner.
For male patients who were sexually active and who were partners of premenopausal women: agreement to use two forms of contraception during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
Significant cardiovascular history:
History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration; Uncontrolled arrhythmia; History of congenital ; (ECG) findings consistent with active ischemic heart disease; Class III or IV cardiac disease; Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic despite antihypertensive medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
75 mg/m\^2 Docetaxel + 20 mg/m\^2 Plinabulin
Drug: Plinabulin
75 mg/m\^2 Docetaxel + 10 mg/m\^2 Plinabulin
Drug: Plinabulin
75 mg/m\^2 Docetaxel + 5 mg/m\^2 Plinabulin
Drug: Plinabulin
75 mg/m\^2 Docetaxel + 6 mg Pegfilgrastim
Drug: Pegfilgrastim
a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Also known as: G-CSF
DSN
Duration of Grade 4 neutropenia (ANC \< 0.5 × 109/L)
Time frame: At the end of Cycle 1 (each cycle is 21 days)
Peak Plasma Concentration (Cmax)
a parameter to establish the pharmacokinetic profile of plinabulin by evaluating the peak plasma concentration (Cmax) of the drug in the blood after administration of a single dose of the drug
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Area Under Curve (AUC)
A parameter to establish the pharmacokinetic profile of plinabulin to describe the variation of the drug concentration in blood plasma as a function of time
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Terminal Half-time (T1/2)
A parameter to establish the pharmacokinetic profile of plinabulin by measuring the time it takes for the concentration of the drug in the plasma to be reduced by 50%
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Volume of Distribution in the Terminal Elimination Phase (Vz)
A parameter to establish the pharmacokinetic profile of plinabulin by evaluating Vz.
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Clearance (Cl)
a parameter to establish the pharmacokinetic profile of plinabulin
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Systolic Blood Pressure
a parameter to establish the pharmacodynamic profile of plinabulin
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Diastolic Blood Pressure
a parameter to establish the pharmacodynamic profile of plinabulin
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
Area Over the Neutropenia Curve
a parameter to establish the pharmacodynamic profile of plinabulin
Time frame: 0, 0.5, 1, 4.5, 24 hours post-dose
| Milestone | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 14 |
| Completed | 11 | 11 | 10 | 9 |
| Not completed | 2 | 3 | 4 | 5 |
Duration of Grade 4 neutropenia (ANC \< 0.5 × 109/L)
| days | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| DSN | 0.15 ± 0.376 | 0.36 ± 0.929 | 0.43 ± 1.089 | 0.29 ± 0.611 |
a parameter to establish the pharmacokinetic profile of plinabulin by evaluating the peak plasma concentration (Cmax) of the drug in the blood after administration of a single dose of the drug
| mg/L | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Peak Plasma Concentration (Cmax) | — | 0.263 ± 0.173 | 0.131 ± 0.086 | 0.066 ± 0.043 |
A parameter to establish the pharmacokinetic profile of plinabulin to describe the variation of the drug concentration in blood plasma as a function of time
| mg*hr/L | Arm 1 | Arm2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Area Under Curve (AUC) | — | 1.22 ± 1.56 | 0.61 ± 0.78 | 0.31 ± 0.39 |
A parameter to establish the pharmacokinetic profile of plinabulin by measuring the time it takes for the concentration of the drug in the plasma to be reduced by 50%
| hrs | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Terminal Half-time (T1/2) | — | 7.38 ± 3.26 | 7.39 ± 1.79 | 7.99 ± 3.69 |
A parameter to establish the pharmacokinetic profile of plinabulin by evaluating Vz.
| L | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Volume of Distribution in the Terminal Elimination Phase (Vz) | — | 198 ± 51 | 248 ± 72 | 154 ± 111 |
a parameter to establish the pharmacokinetic profile of plinabulin
| L/hr | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Clearance (Cl) | — | 22.9 ± 18.0 | 25.0 ± 15.0 | 18.5 ± 23.7 |
a parameter to establish the pharmacodynamic profile of plinabulin
| mm Hg | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Systolic Blood Pressure | — | 136 ± 24 | 134 ± 18.7 | 138 ± 19.5 |
a parameter to establish the pharmacodynamic profile of plinabulin
| mm Hg | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Diastolic Blood Pressure | — | 79.2 ± 11.6 | 84.1 ± 16.8 | 84.8 ± 13.0 |
a parameter to establish the pharmacodynamic profile of plinabulin
| mg*hr/L | Arm 1 | Arm2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Area Over the Neutropenia Curve | — | 0.086 ± 0.815 | 0.111 ± 0.955 | 0.113 ± 0.958 |
Collected over Time of screening until 30 day follow up (5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 1/13 (7.7%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Arm 2 | 1/14 (7.1%) | 2/14 (14.3%) | 12/14 (85.7%) |
| Arm 3 | 1/14 (7.1%) | 2/14 (14.3%) | 12/14 (85.7%) |
| Arm 4 | 1/14 (7.1%) | 2/14 (14.3%) | 12/14 (85.7%) |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Atrial FibrillationCardiac disorders | 1/13 | 0/14 | 0/14 | 0/14 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/13 | 0/14 | 0/14 | 0/14 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/13 | 1/14 | 0/14 | 0/14 |
| VomittingGastrointestinal disorders | 0/13 | 1/14 | 0/14 | 0/14 |
| AstheniaGeneral disorders | 0/13 | 1/14 | 0/14 | 0/14 |
| Disease ProgressionGeneral disorders | 0/13 | 0/14 | 1/14 | 0/14 |
| PneumoniaInfections and infestations | 0/13 | 0/14 | 0/14 | 1/14 |
| Septic ShockInfections and infestations | 0/13 | 1/14 | 0/14 | 0/14 |
| UrosepsisInfections and infestations | 0/13 | 0/14 | 0/14 | 1/14 |
| DehydrationMetabolism and nutrition disorders | 0/13 | 1/14 | 0/14 | 0/14 |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/13 | 7/14 | 5/14 | 9/14 |
| LeukopeniaBlood and lymphatic system disorders | 4/13 | 5/14 | 6/14 | 7/14 |
| AlopeciaSkin and subcutaneous tissue disorders | 5/13 | 4/14 | 7/14 | 1/14 |
| AnaemiaBlood and lymphatic system disorders | 1/13 | 2/14 | 5/14 | 1/14 |
| DiarrhoeaGastrointestinal disorders | 0/13 | 3/14 | 1/14 | 4/14 |
| FatigueGeneral disorders | 1/13 | 1/14 | 3/14 | 4/14 |
| HypertensionVascular disorders | 0/13 | 1/14 | 4/14 | 2/14 |
| LymphopeniaBlood and lymphatic system disorders | 0/13 | 1/14 | 1/14 | 3/14 |
| White Blood Cell Count DecreasedInvestigations | 1/13 | 1/14 | 3/14 | 1/14 |
| Bone PainMusculoskeletal and connective tissue disorders | 1/13 | 1/14 | 0/14 | 3/14 |
| Age, Categorical(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 7 | 9 | 5 | 30 |
| >=65 years | 4 | 7 | 5 | 9 | 25 |
| Age, Continuous(Years) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Total |
|---|---|---|---|---|---|
| Mean | 59.5 ± 8.08 | 63.0 ± 10.44 | 58.6 ± 11.72 | 64.1 ± 10.33 | 61.3 ± 10.24 |
| Sex: Female, Male(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 5 | 5 | 17 |
| Male | 10 | 10 | 9 | 9 | 38 |
| Race (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 4 | 3 | 3 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 10 | 10 | 11 | 11 | 42 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count at Baseline Visit (Pre-dose)(10^9 Cells/L) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Total |
|---|---|---|---|---|---|
| Mean | 9.766 ± 3.4633 | 7.498 ± 2.3376 | 8.870 ± 3.0302 | 8.061 ± 3.9371 | 8.527 ± 3.2641 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Mar 2018, 11 months.
Results were first posted in May 2024, 6 years 1 month after primary completion.
Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NPI 2358
BeyondSpring Pharmaceuticals Inc.